RET alterations resulting in receptor hyperactivation have been identified as causal factors in multiple neoplastic diseases, most notably non-small cell lung carcinoma (NSCLC) [2] and both medullary and papillary thyroid carcinomas (MTC & PTC) [3, 4]. This evidence concerns the gene RET and non-small cell lung carcinoma.